TiGenix CEO Eduardo Bravo assumes leadership of European Biopharmaceutical Enterprises

At the conclusion of the Annual General assembly, EBE, the European trade association that represents European biopharmaceutical companies of all sizes, announced the appointment of Eduardo Bravo, who had previously served as Vice President, to lead a 13 member C-level board for the 2016 – 2018 term.

According to Barbara Freischem, EBE’s Executive Director, their role is to be a “representative voice for emerging bioscience and technology companies in Europe”. She continued by saying that, “Mr. Bravo brings so much to our organization. Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalized medicines within a thriving and innovation ecosystem”.

In his role as President of the EBE Board of Directors, Mr. Bravo stated that the organization’s objective for the near term is to advance the agenda of its stakeholder groups while serving as a platform for regulatory dialogue and entrepreneurial policies. “This is a very exciting time at the EBE. We are well positioned to help new initiatives and cutting-edge technologies advance biopharmaceutical pipelines toward eventual solutions for difficult-to-treat conditions and diseases,” he said.

The EBE Board of Directors represents a unique combination of representatives from small, medium and large biopharmaceutical companies. “It is a pleasure to be working with such a dedicated group of senior industry leaders to support emerging sciences in the search of therapeutic solutions”, Mr. Bravo concluded.